clonidine has been researched along with verapamil in 155 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (24.52) | 18.7374 |
| 1990's | 23 (14.84) | 18.2507 |
| 2000's | 24 (15.48) | 29.6817 |
| 2010's | 61 (39.35) | 24.3611 |
| 2020's | 9 (5.81) | 2.80 |
| Authors | Studies |
|---|---|
| Dresser, MJ; Giacomini, KM; Gray, AT; Terashita, S; Yost, SC; Zhang, L | 1 |
| Giacomini, KM; Schaner, ME; Zhang, L | 1 |
| Nezu, J; Oku, A; Sai, Y; Sakamoto, K; Shimane, M; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
| Nezu, JI; Ohashi, R; Oku, A; Sai, Y; Shimane, M; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Faassen, F; Spanings, H; Vogel, G; Vromans, H | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Akamatsu, M; Fujikawa, M; Nakao, K; Shimizu, R | 1 |
| Cuddon, P; Fleming, A; Floto, RA; Goldsmith, P; Jahreiss, L; O'Kane, CJ; Pask, D; Rubinsztein, DC; Saiki, S; Sarkar, S; Siddiqi, FH; Ttofi, EK; Williams, A | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Andrisano, V; Barril, X; Bartolini, M; Carreiras, Mdo C; de los Ríos, C; García, AG; Huertas, O; León, R; López, B; López, MG; Luque, FJ; Marco-Contelles, J; Rodríguez-Franco, MI; Samadi, A; Villarroya, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Andrisano, V; Arce, MP; Badia, A; Bartolini, M; Camps, P; Clos, MV; Dafni, T; Formosa, X; Galdeano, C; Gómez, E; Huertas, O; Isambert, N; Lavilla, R; Luque, FJ; Mancini, F; Muñoz-Torrero, D; Ramírez, L; Rodríguez-Franco, MI | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Arce, MP; Conde, S; García, AG; González-Muñoz, GC; López, B; López, MG; Pérez, C; Rodríguez-Franco, MI; Villarroya, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Akamatsu, M | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Arce, MP; Conde, S; del Barrio, L; Egea, J; García, AG; González-Muñoz, GC; León, R; López, B; López, MG; Martín-de-Saavedra, MD; Pérez, C; Rodríguez-Franco, MI; Romero, A; Villarroya, M | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Guo, Y; Liu, J; Ma, X; Ma, Z; Ning, X; Tian, C; Wang, X; Zhang, Z; Zhu, R | 1 |
| Chen, J; Chen, X; Huang, L; Li, X; Sun, Y | 1 |
| Andrisano, V; Bartolini, M; Clos, MV; Di Pietro, O; Juárez-Jiménez, J; Lavilla, R; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Ramón, R; Viayna, E; Vicente-García, E | 1 |
| Cheng, C; Du, Y; Guo, Y; Liu, J; Ma, X; Ma, Z; Ning, X; Shi, X; Tian, C; Wang, X; Zhang, Z; Zhu, R | 1 |
| Clos, MV; Di Pietro, O; Espargaró, A; Juárez-Jiménez, J; Lavilla, R; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Sabaté, R | 1 |
| Clos, MV; Di Pietro, O; Espargaró, A; Galdeano, C; Guillou, C; Lamuela-Raventós, RM; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Ragusa, IM; Sabaté, R; Vallverdú-Queralt, A; Viayna, E | 1 |
| Huang, L; Li, X; Meng, F; Miao, H; Sun, Y | 1 |
| Kong, LY; Lan, JS; Li, SY; Pan, LF; Wang, XB; Xie, SS | 1 |
| Artigas, A; Clos, MV; Gbedema, SY; Kelly, JM; Muñoz-Torrero, D; Pérez, B; Sola, I; Taylor, MC; Wright, CW | 1 |
| Deng, Y; Li, Y; Liu, Q; Qiang, X; Sang, Z; Tan, Z; Xiao, G | 1 |
| Dong, G; Guo, PP; Jiang, N; Kong, LY; Lan, JS; Li, ZR; Wang, KD; Wang, XB; Xie, SS | 1 |
| Jiang, N; Kong, LY; Lan, JS; Li, ZR; Wang, KD; Wang, X; Xie, SS; Yu, W | 1 |
| Chang, S; Gao, W; Gao, YX; Liao, H; Pang, T; Qiu, WW; Wang, YJ; Wang, YY; Xu, Y; Xu, YZ; Yang, LF; Yu, LG; Zhang, LY | 1 |
| Berenguer, D; Clos, MV; Di Pietro, O; Fisa, R; Kelly, JM; Lanzoni, A; Lavilla, R; Muñoz-Torrero, D; Pérez, B; Riera, C; Sayago, H; Sola, I; Taylor, MC; Viayna, E; Vicente-García, E | 1 |
| Jiang, N; Kong, LY; Lan, JS; Li, F; Wang, J; Wang, X; Wang, ZM; Wu, JJ; Xie, SS | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bai, P; Chen, C; Hu, K; Li, T; Liu, W; Ma, Q; Pan, W; Peng, K; Sang, Z; Yu, L; Zhang, X | 1 |
| Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G | 1 |
| Alencar, N; Di Pietro, O; Esteban, G; Juárez-Jiménez, J; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Sola, I; Solé, M; Szałaj, N; Unzeta, M; Vázquez, J; Viayna, E | 1 |
| Kong, LY; Li, F; Li, XM; Wang, J; Wang, XB; Wang, ZM; Wu, JJ | 1 |
| Cai, P; Kong, LY; Liu, QH; Wang, XB; Wang, ZM; Wu, JJ; Xu, DQ; Yang, XL | 1 |
| Artigas, A; Clos, MV; Kelly, JM; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Sola, I; Taylor, MC; Viayna, E; Wright, CW | 1 |
| Cai, P; Kong, L; Liu, Q; Wang, KDG; Wang, X; Wang, Z; Wu, J; Yang, X | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Yang, X; Zheng, Y | 1 |
| Ai, J; Deng, Y; Li, Y; Liu, Q; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, X | 1 |
| Guo, QL; Huang, SL; Huang, ZS; Li, D; Liu, ZQ; Ou, TM; Tan, JH; Wang, HG; Wang, N; Wu, JQ; Xia, CL | 1 |
| Arce, MP; Conde, S; Egea, J; Gil, C; León, R; López, MG; Monjas, L; Pérez, C; Rodríguez-Franco, MI; Villarroya, M | 1 |
| Bai, P; Leng, C; Li, X; Liu, W; Ma, Q; Pan, W; Sang, Z; Tan, Z; Wang, K; Xu, Q; Yang, Y; Yu, L | 1 |
| Liu, W; Ma, Q; Pan, W; Sang, Z; Wang, K; Yu, L | 1 |
| Cai, P; Kong, LY; Li, F; Liu, QH; Wang, J; Wang, XB; Wu, JJ; Yang, XL | 1 |
| Hao, L; Huang, W; Jin, H; Liang, L; Niu, Y; Wang, C; Wang, W; Xu, F; Xu, P; Yan, G | 1 |
| Cai, P; Kong, LY; Li, F; Liu, QH; Wang, J; Wang, XB; Wu, JJ; Yang, HL; Yang, XL | 1 |
| Cai, P; Kong, LY; Li, F; Wang, J; Wang, XB; Wu, JJ; Yang, XL | 1 |
| Cai, P; Fang, SQ; Kong, LY; Liu, QH; Tang, YW; Wang, C; Wang, XB; Yang, HL; Yang, XL | 1 |
| Han, X; Liu, W; Ma, Q; Sang, Z; Wang, H; Wang, K; Ye, M; Yu, L | 2 |
| Huang, Q; Jiang, N; Li, Q; Liang, N; Liu, J; Xie, SS | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Xu, R; Yang, J; Zhang, X | 1 |
| Deng, Y; Li, Y; Liu, H; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, Z; Zhang, X; Zheng, Y | 1 |
| An, Q; Deng, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Wang, T; Yang, T; Yang, Y; Zhang, T | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Tian, C; Yang, Z | 1 |
| Cai, P; Kong, LY; Liu, QH; Shi, CJ; Tang, YW; Wang, XB; Yang, HL; Yang, XL | 1 |
| An, B; Hu, J; Huang, L; Li, X; Li, Z; Pan, T | 1 |
| Deng, Y; He, Y; Li, W; Liu, H; Qiang, X; Song, Q; Tan, Z; Ye, C | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K; Zhang, P | 1 |
| Andrisano, V; Barniol-Xicota, M; Bartolini, M; De Simone, A; Espargaró, A; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Pivetta, D; Pont, C; Sabate, R; Sureda, FX; Turcu, AL; Vázquez, S | 1 |
| Fan, X; Liu, W; Sang, Z; Shi, J; Wang, K; Yang, D; Zhang, P; Zhang, Z; Zhu, G | 1 |
| Bai, P; Cheng, X; Cheng, Y; Lu, X; Sang, Z; Shi, J; Wang, K; Yang, J; Zhang, P; Zhang, Q; Zheng, C | 1 |
| Chen, Y; Feng, F; He, S; Li, Q; Liao, Q; Liu, W; Liu, Y; Lu, W; Sun, H; Xing, S; Xiong, B; Yang, H | 1 |
| Chen, L; Chen, Y; Duan, Y; Feng, F; Huang, J; Jiang, X; Liu, C; Liu, W; Qu, W; Sun, H; Wang, Y; Zhou, J | 1 |
| Chen, T; Chen, Y; Feng, F; Jiang, X; Li, Q; Liu, C; Liu, W; Lyu, W; Sun, H; Wang, S; Wang, Y; Xing, C | 1 |
| Huang, M; Jiang, N; Kong, LY; Lan, JS; Wang, XB; Yin, FC | 1 |
| Ji, L; Kong, L; Li, S; Liu, X; Lu, D; Luo, H; Peng, W; Qu, L; Wang, C; Wang, X; Yin, F | 1 |
| Chen, H; Ding, H; Gao, Y; Jiang, X; Liu, W; Liu, X; Tian, L; Xu, Z; Zhao, Q | 1 |
| Chen, L; Lei, Z; Sun, J; Sun, X; Wang, Y; Yue, S | 1 |
| Brea, JM; Companys-Alemany, J; Griñán-Ferré, C; Johnson, JW; Kurnikova, MG; Loza, MI; Pallàs, M; Patel, DS; Pérez, B; Phillips, MB; Soto, D; Sureda, FX; Turcu, AL; Vázquez, S | 1 |
| Denkl, P; Haas, Th | 1 |
| Koropova, GE; Serdiuchenko, IIa; Shcherbinina, MB | 1 |
| Benedek, G; Horváth, G; Szikszay, M | 2 |
| Espinoza, M; Flores, R; Ortiz, S; Schnur, P; Vallejos, S; Wainwright, M | 1 |
| Akaike, M; Hirai, M; Kumai, T; Masubuchi, Y; Tanaka, M; Watanabe, M | 1 |
| Ernsberger, P; Felsen, D; Hensley, ML; Meeley, MP; Reis, DJ | 1 |
| Schnur, P | 1 |
| García-Barrado, MJ; Moratinos, J; Reverte, M | 1 |
| Mustafa, AA | 1 |
| Babaian, AS; Dzhandzhapanian, AZ; Gurgenian, SV; Mikaelian, ES | 1 |
| Burris, JF; Cook, ME; Papademetriou, V; Wallin, JD; Weidler, DJ | 1 |
| Donowitz, M; Homaidan, FR; Sharp, GW; Torres, A | 1 |
| Greenidge, E; Wali, FA | 1 |
| Cools, V; Cox, E; Houvenaghel, A | 1 |
| Chiba, S; Ito, T | 1 |
| Cusolito, S; Donowitz, M; el Sabban, ME; Homaidan, FR; Sharp, WG; Weiland, GA; Wicks, J | 1 |
| Cookson, JC | 1 |
| Kannan, MS; Seip, AE | 1 |
| Akopian, LM; Basem, AS; Ivleva, AIa; Krasnobaeva, GM; Moiseev, VS | 1 |
| Forster, P; Stone, TW | 1 |
| Degnan, KJ; May, SA | 1 |
| Baranowska, B; Cantin, M; Genest, J; Gutkowska, J; Talbot, P | 1 |
| Geng, WP; Xu, SY | 1 |
| Akahane, K; Chiba, S; Furukawa, Y; Haniuda, M; Ogiwara, Y | 1 |
| Kobinger, W; Lillie, C | 3 |
| Baeyens, JM; Esposito, E; Ossowska, G; Samanin, R | 1 |
| Giannini, AJ; Houser, WL; Kerr, L | 1 |
| Gaillard-Plaza, G; Lhoste, F; Montastruc, JL; Montastruc, P; Rostin, M | 1 |
| Kaschube, M; Zetler, G | 1 |
| Nast, HP; Philipp, T | 1 |
| Buckalew, VM; Strandhoy, JW; Wolff, DW | 2 |
| Galzin, AM; Langer, SZ | 1 |
| Qian, JQ; Timmermans, PB; Van Meel, JC; Van Zwieten, PA | 1 |
| de Jonge, A; Kalkman, HO; Mathy, MJ; Thoolen, MJ; Timmermans, PB; van Meel, JC; van Zwieten, PA; Wilffert, B | 1 |
| Janssens, W; Verhaeghe, R | 1 |
| Glossmann, H; Hornung, R | 1 |
| De Mey, J; Vanhoutte, PM | 1 |
| Wikberg, JE | 1 |
| Addonizio, VP; Barnathan, ES; Shattil, SJ | 1 |
| Jarrott, B; Nayler, WG; Thompson, JE | 1 |
| Brandt, D | 1 |
| Abichequer, MB; Maciel, RM; Spritzer, N; Spritzer, TS | 1 |
| Nghiem, C; Swamy, VC; Triggle, DJ | 1 |
| Balazs, T; El-Hage, A; West, WL | 1 |
| Balakumaran, K; Simoons, ML | 1 |
| Bender, F | 1 |
| Baeyens, JM; Barrios, M; Robles, I | 1 |
| Borycz, J; Bugajski, AJ; Bugajski, J; Gadek-Michalska, A | 1 |
| Lasova, L; Mutafova-Yambolieva, V; Radomirov, R; Staneva-Stoytcheva, D | 1 |
| Newman, PS; Soltis, EE; Trowbridge, JL | 1 |
| Bojanova, E; Genkova-Papazova, M; Lazarova-Bakarova, M; Petkova, B | 1 |
| Wong, KK | 1 |
| Boselli, C; Grana, E | 1 |
| Kitazawa, T; Maezono, Y; Taneike, T | 1 |
| Nath, C; Srivastava, SK | 1 |
| Brodacz, B; Holzer-Petsche, U; Horváth, G | 2 |
| Abdollah, H; Ghali, WA; Moritz, S; Sanfilippo, AJ; Simpson, CS | 1 |
| Groschner, K; Masui, H; Wakabayashi, I | 1 |
| Camm, AJ; Yusuf, S | 1 |
| Dkhar, SA; Naveen, AT; Peddyreddy, MK; Ramaswamy, S; Shewade, DG | 1 |
| Kubo, Y | 1 |
| Floerl, S; Hagos, Y; Kuehne, A | 1 |
4 review(s) available for clonidine and verapamil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug treatment of bipolar depression and mania.
Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Bromocriptine; Carbamazepine; Cholinesterase Inhibitors; Clonidine; Depressive Disorder; Double-Blind Method; Drug Therapy, Combination; Humans; Lithium; Monoamine Oxidase Inhibitors; Phosphatidylcholines; Tryptophan; Valproic Acid; Verapamil | 1985 |
Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven?
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Benzazepines; Calcium Channel Blockers; Clonidine; Diagnosis, Differential; Humans; Isoindoles; Ivabradine; Phthalimides; Pyrimidines; Sinoatrial Node; Tachycardia, Sinus; Vasodilator Agents; Verapamil | 2003 |
[Carrier-mediated Transport of Cationic Drugs across the Blood-Tissue Barrier].
Topics: Angiogenesis Inhibitors; Biological Transport; Blood-Brain Barrier; Blood-Retinal Barrier; Cation Transport Proteins; Clonidine; Drug Carriers; Humans; Nervous System Diseases; Neuroprotective Agents; Propranolol; Pyrilamine; Verapamil | 2015 |
4 trial(s) available for clonidine and verapamil
| Article | Year |
|---|---|
Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Blood Pressure; Clonidine; Double-Blind Method; Female; Humans; Hypertension; Male; Patient Compliance; Quality of Life; Surveys and Questionnaires; Verapamil | 1991 |
Clonidine and verapamil in the treatment of mania.
Topics: Bipolar Disorder; Clonidine; Humans; Verapamil | 1986 |
[Treatment of diuretic-resistant arterial hypertension - crossed comparative study of verapamil and clonidine].
Topics: Calcium; Clinical Trials as Topic; Clonidine; Female; Humans; Hypertension; Male; Sodium; Verapamil | 1981 |
Clinical assessment of clonidine in the treatment of new-onset rapid atrial fibrillation: a prospective, randomized clinical trial.
Topics: Acute Disease; Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Clonidine; Digoxin; Female; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Treatment Outcome; Verapamil | 2001 |
147 other study(ies) available for clonidine and verapamil
| Article | Year |
|---|---|
Cloning and functional expression of a human liver organic cation transporter.
Topics: Amino Acid Sequence; Animals; Base Sequence; Carrier Proteins; Cloning, Molecular; DNA, Complementary; Humans; Liver; Membrane Proteins; Molecular Sequence Data; Oocytes; Organic Cation Transporter 1; Polymerase Chain Reaction; Rats; RNA, Messenger; Sequence Homology, Amino Acid; Species Specificity; Tissue Distribution; Xenopus laevis | 1997 |
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
Topics: Carrier Proteins; Corticosterone; HeLa Cells; Humans; Membrane Proteins; Midazolam; Organic Cation Transporter 1; Permeability; Recombinant Proteins; Structure-Activity Relationship; Tetraethylammonium Compounds; Transfection | 1998 |
Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations.
Topics: Animals; Biological Transport, Active; Carrier Proteins; Cell Line; Gene Expression; Humans; Hydrogen-Ion Concentration; Membrane Potentials; Membrane Proteins; Membrane Transport Proteins; Oocytes; Organic Cation Transport Proteins; Quinidine; RNA, Messenger; Symporters; Tetraethylammonium Compounds; Xenopus laevis | 1999 |
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
Topics: Biological Transport, Active; Carnitine; Carrier Proteins; Cations; Cells, Cultured; Dose-Response Relationship, Drug; Embryo, Mammalian; Humans; Hydrogen-Ion Concentration; Kidney; Membrane Proteins; Organic Cation Transport Proteins; Sodium; Solute Carrier Family 22 Member 5; Stereoisomerism | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Caco-2 Cells; Cell Membrane Permeability; Heterocyclic Compounds; Humans; Protein Transport | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
QSAR study on permeability of hydrophobic compounds with artificial membranes.
Topics: Biological Transport; Caco-2 Cells; Drug Evaluation, Preclinical; Humans; Hydrophobic and Hydrophilic Interactions; Membranes, Artificial; Permeability; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship | 2007 |
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
Topics: Animals; Autophagy; Calcium Channels, L-Type; Clonidine; Cyclic AMP; Humans; Huntington Disease; Imidazoline Receptors; Minoxidil; Protein Kinases; Signal Transduction; TOR Serine-Threonine Kinases; Type C Phospholipases; Verapamil | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholinesterase; Calcium; Calcium Channel Blockers; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytosol; Dihydropyridines; Humans; Hydrogen Peroxide; Kinetics; Ligands; Models, Molecular; Peptide Fragments; Permeability; Tacrine | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Drug Design; Humans; Isomerism; Membranes, Artificial; Mice; Models, Molecular; Molecular Conformation; Permeability; Protein Binding; Tacrine | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Catalytic Domain; Cattle; Cell Death; Cell Line, Tumor; Cell Survival; Cholinergic Agents; Cholinesterase Inhibitors; Esters; Glutamic Acid; Humans; Hydrophobic and Hydrophilic Interactions; Neuroprotective Agents; Permeability; Piperidines; Protein Binding | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Importance of physicochemical properties for the design of new pesticides.
Topics: Anabasine; Animals; Biological Availability; Cell Membrane Permeability; Chemical Phenomena; Drug Design; Humans; Imidazoles; Insecticides; Neonicotinoids; Nitro Compounds; Pesticides; Quantitative Structure-Activity Relationship; Receptors, Nicotinic | 2011 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cell Death; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Okadaic Acid; Peptide Fragments; Phenothiazines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Design, synthesis and pharmacological evaluation of (E)-3,4-dihydroxy styryl sulfonamides derivatives as multifunctional neuroprotective agents against oxidative and inflammatory injury.
Topics: Animals; Blood-Brain Barrier; Caffeic Acids; Cell Line, Tumor; Drug Design; Free Radical Scavengers; Mice; Microglia; Neuroprotective Agents; Nitric Oxide; Oxidative Stress; Phenylethyl Alcohol; Rats; Stereoisomerism; Sulfonamides | 2013 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electrophorus; Humans; Isoflavones; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Swine; Tacrine | 2013 |
1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.
Topics: Acetylcholinesterase; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Membranes, Artificial; Models, Biological; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Naphthyridines; Permeability; Protein Binding | 2014 |
Design, synthesis, and biological evaluation of (e)-3,4-dihydroxystyryl aralkyl sulfones and sulfoxides as novel multifunctional neuroprotective agents.
Topics: Animals; Blood-Brain Barrier; Drug Design; Free Radical Scavengers; Humans; Neuroprotective Agents; Nitric Oxide; Oxidopamine; PC12 Cells; Rats; Sulfones; Sulfoxides | 2014 |
Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Naphthyridines; Structure-Activity Relationship; Tacrine; tau Proteins; Tauopathies | 2014 |
Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.
Topics: Acetylcholinesterase; Aminoquinolines; Amyloid beta-Peptides; Antioxidants; Catechols; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Structure; Protein Aggregates; Protein Aggregation, Pathological; Structure-Activity Relationship; tau Proteins | 2014 |
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Humans; Indans; Inhibitory Concentration 50; Ligands; Peptide Fragments; Permeability; Protein Aggregates | 2014 |
Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Carbolines; Cell Line; Chelating Agents; Cholinesterase Inhibitors; Drug Design; Electrophorus; Horses; Humans; Molecular Docking Simulation; Protein Aggregation, Pathological; Tacrine | 2014 |
Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines.
Topics: Antimalarials; Antiprotozoal Agents; Humans; Molecular Structure; Structure-Activity Relationship | 2014 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyrylcholinesterase; Carbamates; Cell Line; Chelating Agents; Cholinesterase Inhibitors; Cognition; Glucuronates; Humans; Mice; Molecular Docking Simulation; Neuroprotective Agents; Rats | 2015 |
Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties.
Topics: Alzheimer Disease; Animals; Antioxidants; Biphenyl Compounds; Blood-Brain Barrier; Cell Survival; Chemical and Drug Induced Liver Injury; Cholinesterase Inhibitors; Chromans; Drug Design; In Vitro Techniques; Kinetics; Male; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; PC12 Cells; Picrates; Rats; Swine; Tacrine | 2015 |
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cells, Cultured; Cholinesterase Inhibitors; Coumarins; Drug Design; Erythrocytes; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroblastoma; Piperazines; Tacrine | 2015 |
Design, synthesis and biological evaluation of tricyclic diterpene derivatives as novel neuroprotective agents against ischemic brain injury.
Topics: Animals; Brain Injuries; Cell Survival; Diterpenes; Dose-Response Relationship, Drug; Drug Design; Glutamic Acid; Molecular Structure; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2015 |
Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
Topics: Acetylcholinesterase; Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophorus; Leishmania infantum; Molecular Structure; Parasitic Sensitivity Tests; Quinolines; Rats; Structure-Activity Relationship; Trypanosoma brucei brucei; Trypanosoma cruzi | 2015 |
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Cholinesterases; Coumarins; Donepezil; Dose-Response Relationship, Drug; Drug Design; Eels; Humans; Indans; Models, Molecular; Molecular Structure; Molecular Targeted Therapy; Piperidines; Structure-Activity Relationship | 2016 |
Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alkanes; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Coumaric Acids; Drug Design; Drug Evaluation, Preclinical; Ethylamines; Humans; Hydrogen Peroxide; Neuroprotective Agents; PC12 Cells; Rats | 2016 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; Chelating Agents; Copper; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Swine | 2016 |
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Structure-Activity Relationship | 2016 |
Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Catalytic Domain; Cell Line, Tumor; Chelating Agents; Cholinesterase Inhibitors; Donepezil; Electrophorus; Horses; Humans; Indans; Indoles; Iron; Kinetics; Melatonin; Molecular Docking Simulation; Peptide Fragments; Piperidines; Protein Multimerization; Rats; Zinc | 2016 |
Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Copper; Donepezil; Drug Design; Humans; Indans; Kinetics; Liver; Mice; Models, Molecular; Peptide Fragments; Piperidines; Protein Aggregates; Protein Conformation | 2016 |
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
Topics: Aminoquinolines; Brain; Dose-Response Relationship, Drug; Molecular Structure; Parasitic Sensitivity Tests; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei | 2016 |
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
Topics: Animals; Apoptosis; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Mice; Mice, Inbred Strains; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Rats; Small Molecule Libraries; Structure-Activity Relationship | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Isoflavones; Mannich Bases; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Mannich Bases; Neuroprotective Agents; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rivastigmine; Structure-Activity Relationship; Swine | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Blood-Brain Barrier; Edaravone; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Structure, Tertiary | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors; Humans; Kinetics; Models, Molecular; Monoamine Oxidase Inhibitors; Thioxanthenes; Xanthones | 2017 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; Cholinesterase Inhibitors; Drug Design; Glutathione; Humans; Quinolines; Reactive Oxygen Species | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Donepezil; Glutamates; Hippocampus; Humans; Indans; Neuroprotective Agents; Piperidines; Rats; Solid-Phase Synthesis Techniques | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumaric Acids; Drug Design; Eels; Humans; Memory Disorders; Mice; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quinolines; Swine | 2017 |
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Binding Sites; Blood-Brain Barrier; Chromones; Copper; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Protein Structure, Tertiary; Rats; Reactive Oxygen Species; Structure-Activity Relationship | 2017 |
2-Substituted-thio-N-(4-substituted-thiazol/1H-imidazol-2-yl)acetamides as BACE1 inhibitors: Synthesis, biological evaluation and docking studies.
Topics: Acetamides; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; HEK293 Cells; Humans; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2017 |
Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Mice; Mice, Inbred Strains; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; PC12 Cells; Protein Aggregates; Rats; Structure-Activity Relationship | 2017 |
Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzylamines; Blood-Retinal Barrier; Butyrylcholinesterase; Cell Death; Cholinergic Agents; Cholinesterase Inhibitors; Cinnamates; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Hydrogen Peroxide; Imines; Ligands; Lipopolysaccharides; Mice; Microglia; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; PC12 Cells; Peptide Fragments; Protein Aggregates; Rats; Salicylates; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phthalimides; Protein Structure, Tertiary; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Permeability; Phenols; Piperazines; Protein Structure, Tertiary; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Kinetics; Male; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Peptide Fragments; Protein Aggregates; Range of Motion, Articular; Structure-Activity Relationship; Thiocarbamates | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Survival; Chalcones; Chelating Agents; Copper; Drug Design; Flurbiprofen; Humans; Lipopolysaccharides; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nitric Oxide; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Permeability; Protein Aggregates; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2018 |
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
Topics: Antineoplastic Agents; Antitubercular Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrroles; Quinoxalines; Structure-Activity Relationship | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship | 2018 |
Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Dimerization; Humans; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; Prenylation; Rats; Resveratrol; Structure-Activity Relationship | 2019 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Design; Humans; Ligands; Mice; Rats; Rolipram | 2019 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cholinesterase Inhibitors; Drug Design; Drug Discovery; Electrophorus; Flurbiprofen; Humans; Mannich Bases; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Rats; Swine | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Eels; Female; Horses; Humans; Male; Maze Learning; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase Inhibitors; Drug Design; Eels; Horses; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates | 2019 |
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Tacrine | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Development; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Transport; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Chelating Agents; Cholinesterase Inhibitors; Coordination Complexes; Copper; Drug Design; Female; Humans; Male; Memory Disorders; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Protein Binding; Scopolamine; Structure-Activity Relationship | 2019 |
Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor.
Topics: Aminoquinolines; Animals; Benzimidazoles; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Discovery; Drug Evaluation, Preclinical; Female; Humans; Male; Mice, Inbred ICR; Microsomes, Liver; Molecular Docking Simulation; Molecular Dynamics Simulation; Neuroprotective Agents; Protein Binding; Small Molecule Libraries | 2020 |
Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
Topics: Acetylcholinesterase; Acridines; Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Glycogen Synthase Kinase 3; Mice; Molecular Docking Simulation; Molecular Targeted Therapy; Morris Water Maze Test; Phosphorylation; Protein Conformation; tau Proteins; Thiazoles | 2020 |
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Glycogen Synthase Kinase 3 beta; Humans; Molecular Structure; Neuroprotective Agents; Protein Kinase Inhibitors; Pyridines; Structure-Activity Relationship; Thiazoles; Tumor Cells, Cultured | 2021 |
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Topics: | 2020 |
Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Antioxidants; Aspartic Acid Endopeptidases; Azoles; Binding Sites; Blood-Brain Barrier; Cyclic S-Oxides; Drug Design; Humans; Interleukin-6; Isoindoles; Ligands; Mitochondria; Molecular Docking Simulation; Neuroprotective Agents; NF-E2-Related Factor 2; Organoselenium Compounds; Oxidative Stress; Peptide Fragments; Reactive Oxygen Species; Selenium; Signal Transduction; Thiadiazines | 2021 |
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Dyrk Kinases; Glycogen Synthase Kinase 3 beta; Harmine; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2021 |
Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Binding Sites; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Rats | 2022 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Receptors, N-Methyl-D-Aspartate | 2022 |
[Therapy of hypertensive crises].
Topics: Acute Disease; Adrenal Gland Neoplasms; Antihypertensive Agents; Clonidine; Diazoxide; Dihydralazine; Guanethidine; Humans; Hypertension; Hypertension, Malignant; Hypertension, Renal; Methyldopa; Nitroprusside; Pheochromocytoma; Reserpine; Verapamil | 1977 |
[Segmental reflexes after sciatic nerve damage in rats given thyroxine].
Topics: Animals; Clonidine; Decerebrate State; Female; Injections, Intraperitoneal; Propranolol; Rats; Reflex; Sciatic Nerve; Synapses; Synaptic Transmission; Thyroxine; Verapamil | 1992 |
Potentiated hypnotic action with a combination of fentanyl, a calcium channel blocker and an alpha 2-agonist in rats.
Topics: Adrenergic alpha-Agonists; Animals; Clonidine; Dose-Response Relationship, Drug; Drug Synergism; Fentanyl; Hypnosis, Anesthetic; Injections, Subcutaneous; Male; Rats; Rats, Inbred Strains; Time Factors; Verapamil | 1992 |
Blocking naloxone-precipitated withdrawal in rats and hamsters.
Topics: Animals; Behavior, Animal; Clonidine; Cricetinae; Drug Implants; Mesocricetus; Morphine Dependence; Naloxone; Nifedipine; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Verapamil; Yawning | 1992 |
Disturbance or relatively important actions of antihypertensives, antifungal agent and opiate antagonist to the testicular steroidogenesis in rat.
Topics: Androstenedione; Animals; Antifungal Agents; Antihypertensive Agents; Clonidine; Estradiol; Ketoconazole; Male; Naloxone; Narcotic Antagonists; Prazosin; Rats; Testis; Testosterone; Verapamil | 1992 |
Evidence for a bioactive clonidine-displacing substance in peripheral tissues and serum.
Topics: Adrenal Glands; Adrenalectomy; Animals; Brain Chemistry; Clonidine; Gastric Fundus; Male; Muscle Contraction; Radioimmunoassay; Rats; Rats, Inbred Strains; Tissue Extracts; Verapamil | 1992 |
Morphine withdrawal in the hamster.
Topics: Animals; Clonidine; Cricetinae; Morphine; Naloxone; Nifedipine; Stereotyped Behavior; Substance Withdrawal Syndrome; Verapamil | 1992 |
Role of alpha-adrenoceptors in control of plasma potassium in conscious rabbits.
Topics: Animals; Apamin; Calcium Channels; Clonidine; Dioxanes; Ethanolamines; Hyperkalemia; Idazoxan; Potassium; Prazosin; Rabbits; Receptors, Adrenergic, alpha; Verapamil | 1991 |
Rapid desensitization of central beta-adrenoceptors in rat after subacute treatment with imipramine and calcium entry blockers.
Topics: 1-Propanol; Animals; Calcium Channel Blockers; Clonidine; Diltiazem; DOM 2,5-Dimethoxy-4-Methylamphetamine; Drinking Behavior; Fenclonine; Imipramine; Isoproterenol; Ketanserin; Nicardipine; Nifedipine; Oxidopamine; Rats; Receptors, Adrenergic, beta; Verapamil | 1991 |
Efficacy of intravenous verapamil in arterial hypertension refractory to three-step antihypertensive therapy.
Topics: Adult; Antihypertensive Agents; Clonidine; Echocardiography; Female; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension; Hypertension, Renal; Infusions, Intravenous; Male; Methyldopa; Middle Aged; Nifedipine; Ventricular Function, Left; Verapamil | 1991 |
Electrolyte transport in piglets infected with transmissible gastroenteritis virus. Stimulation by verapamil and clonidine.
Topics: Animals; Biological Transport, Active; Chlorides; Clonidine; Gastroenteritis, Transmissible, of Swine; Intestinal Absorption; Jejunum; Sodium; Stimulation, Chemical; Swine; Verapamil; Water-Electrolyte Balance | 1991 |
Enhancement of fentanyl analgesia by clonidine plus verapamil in rats.
Topics: Animals; Clonidine; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Fentanyl; Injections, Subcutaneous; Male; Nociceptors; Rats; Rats, Inbred Strains; Verapamil | 1990 |
Comparative effects of verapamil and D-600 on the contractile responses produced by neurotransmitters and depolarizing agents in the rat isolated seminal vesicle.
Topics: Acetylcholine; Animals; Carbachol; Clonidine; Gallopamil; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth; Neuromuscular Depolarizing Agents; Neurotransmitter Agents; Norepinephrine; Phenylephrine; Potassium Chloride; Rats; Rats, Inbred Strains; Seminal Vesicles; Verapamil | 1989 |
Effect of antisecretory drugs on experimentally induced weanling diarrhoea in piglets.
Topics: Animals; Animals, Newborn; Chlorpromazine; Clonidine; Diarrhea; Disease Models, Animal; Escherichia coli Infections; Female; Gastroenteritis, Transmissible, of Swine; Propranolol; Swine; Swine Diseases; Verapamil | 1989 |
Effects of calcium antagonists on alpha-adrenoceptor mediated vasoconstrictions of the canine intermediate auricular artery.
Topics: Animals; Arteries; Clonidine; Diltiazem; Dogs; Female; In Vitro Techniques; Male; Norepinephrine; Phenylephrine; Potassium Chloride; Receptors, Adrenergic, alpha; Skin; Vasoconstriction; Verapamil | 1987 |
Ca2+ channel blockers interact with alpha 2-adrenergic receptors in rabbit ileum.
Topics: Animals; Calcium Channel Blockers; Clonidine; Diltiazem; Egtazic Acid; Electrolytes; Ileum; In Vitro Techniques; Intestinal Mucosa; Kinetics; Male; Membrane Potentials; Nifedipine; Rabbits; Receptors, Adrenergic, alpha; Verapamil; Yohimbine | 1988 |
Mechanisms of alpha-adrenoceptor mediated contractions of rat mesenteric artery.
Topics: Adrenergic alpha-Agonists; Animals; Azepines; Clonidine; In Vitro Techniques; Kinetics; Male; Mesenteric Arteries; Muscle, Smooth, Vascular; Nifedipine; Nitrendipine; Norepinephrine; Phenylephrine; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Vasoconstriction; Verapamil | 1986 |
[Hemodynamic effect of a combination of prazosin with cardiac depressants in the treatment of hypertension].
Topics: Anti-Arrhythmia Agents; Celiprolol; Clonidine; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension; Male; Prazosin; Propanolamines; Propranolol; Verapamil | 1988 |
Purine effects on (3H)-clonidine binding to rat brain.
Topics: Animals; Brain; Clonidine; Diazepam; In Vitro Techniques; Kinetics; Male; Phenylisopropyladenosine; Purines; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Tritium; Verapamil | 1986 |
Converging adrenergic and cholinergic mechanisms in the inhibition of Cl secretion in fish opercular epithelium.
Topics: Acetylcholine; Animals; Calcium; Chlorine; Clonidine; Cyclic AMP; Dantrolene; Epithelium; Female; Fishes; Killifishes; Male; Receptors, Adrenergic; Receptors, Cholinergic; Trifluoperazine; Verapamil | 1985 |
Plasma immunoreactive atrial natriuretic factor is inhibited by selective blockade of alpha 2-adrenergic receptors in conscious Sprague-Dawley rats.
Topics: Animals; Atrial Natriuretic Factor; Calcium; Clonidine; Drug Interactions; Female; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Receptors, Opioid; Verapamil; Yohimbine | 1987 |
[Relationship between clonidine analgesia and the calcium cation].
Topics: Analgesics; Animals; Calcium Chloride; Clonidine; Egtazic Acid; Male; Pain; Radioligand Assay; Rats; Sensory Thresholds; Verapamil | 1987 |
Bradycardic effects of AQ-A 39 (falipamil) in situ and in isolated, blood-perfused dog hearts. Comparison with alinidine and verapamil.
Topics: Animals; Cardiovascular Agents; Clonidine; Dogs; Dose-Response Relationship, Drug; Heart; Heart Atria; Heart Rate; Isoindoles; Myocardial Contraction; Phthalimides; Verapamil | 1988 |
Investigations differentiating the mechanism of specific bradycardic agents from that of calcium channel blockers.
Topics: Animals; Calcium Channel Blockers; Cardiotonic Agents; Clonidine; Electrophysiology; Guinea Pigs; Imidazoles; In Vitro Techniques; Isoindoles; Myocardial Contraction; Phthalimides; Sinoatrial Node; Verapamil | 1987 |
Effects of peripheral and central administration of calcium channel blockers in the naloxone-precipitated abstinence syndrome in morphine-dependent rats.
Topics: Animals; Body Weight; Brain; Calcium Channel Blockers; Clonidine; Diarrhea; Flunarizine; Injections, Intraventricular; Male; Morphine Dependence; Naloxone; Rats; Substance Withdrawal Syndrome; Verapamil | 1987 |
[Role of the adrenal medulla in the effect of antihypertensive drugs].
Topics: Adrenal Medulla; Animals; Antihypertensive Agents; Blood Pressure; Clonidine; Dihydralazine; Dogs; Female; Heart Rate; Male; Phentolamine; Propranolol; Verapamil | 1985 |
Importance of frequency and pulse with in field stimulation of the mouse vas deferens: different behaviour of twitch-inhibiting drugs.
Topics: Animals; Calcium; Clonidine; D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; Electric Stimulation; Enkephalin, Methionine; In Vitro Techniques; Male; Mice; Muscle Contraction; Muscle, Smooth; Nifedipine; Procaine; Tetrodotoxin; Vas Deferens; Verapamil | 1985 |
[Hypertensive emergencies].
Topics: Brain Edema; Clonidine; Diazoxide; Digitalis Glycosides; Diuretics; Drug Combinations; Emergencies; Ferricyanides; Ganglionic Blockers; Guanethidine; Humans; Hydralazine; Hypertension; Hypertension, Malignant; Hypnotics and Sedatives; Intensive Care Units; Methyldopa; Minoxidil; Nitric Oxide; Pheochromocytoma; Reserpine; Verapamil | 1974 |
Renal alpha 1- and alpha 2-adrenoceptor mediated vasoconstriction in dogs: comparison of phenylephrine, clonidine, and guanabenz.
Topics: Animals; Calcium; Clonidine; Denervation; Dogs; Drug Interactions; Female; Guanabenz; Guanidines; Kidney; Male; Phenylephrine; Prazosin; Receptors, Adrenergic, alpha; Renal Circulation; Vasoconstriction; Verapamil; Yohimbine | 1984 |
Renal alpha 1- and alpha 2-adrenoceptor mediated vasoconstriction in dogs.
Topics: Animals; Calcium; Clonidine; Dogs; Dose-Response Relationship, Drug; Guanabenz; Kidney; Phenylephrine; Prazosin; Receptors, Adrenergic, alpha; Renal Circulation; Vasoconstriction; Verapamil; Yohimbine | 1984 |
Presynaptic alpha 2-adrenoceptor antagonism by verapamil but not by diltiazem in rabbit hypothalamic slices.
Topics: Adrenergic alpha-Antagonists; Animals; Benzazepines; Calcium Channel Blockers; Clonidine; Cocaine; Diltiazem; Epinephrine; Hypothalamus; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Norepinephrine; Rabbits; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Verapamil | 1983 |
Differential inhibition of alpha 2-adrenoceptor-mediated pressor responses by (+)- and (-)-verapamil in pithed rats.
Topics: Adrenergic alpha-Antagonists; Animals; Azepines; Blood Pressure; Clonidine; Male; Rats; Rats, Inbred Strains; Spinal Cord; Stereoisomerism; Verapamil | 1983 |
Differential effect of calcium entry blockers on alpha 1-adrenoceptor-mediated vasoconstriction in vivo.
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Calcium Channel Blockers; Catecholamines; Clonidine; Ethanolamines; Imidazoles; Imidazolines; Male; Methoxamine; Nifedipine; Phenylephrine; Rats; Rats, Inbred Strains; Vasoconstriction; Verapamil | 1983 |
Sources of calcium used during alpha 1- and alpha 2-adrenergic contractions in canine saphenous veins.
Topics: Adrenergic alpha-Agonists; Animals; Calcium; Clonidine; Dogs; Dose-Response Relationship, Drug; Female; In Vitro Techniques; Isometric Contraction; Male; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Phenylephrine; Saphenous Vein; Verapamil | 1984 |
Calcium- and potassium-channel blockers interact with alpha-adrenoceptors.
Topics: Aminopyridines; Animals; Brain; Calcium; Clonidine; Gallopamil; Guanidines; Ion Channels; Myocardium; Potassium; Prazosin; Rats; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Tetraethylammonium Compounds; Verapamil | 1980 |
Uneven distribution of postjunctional alpha 1-and alpha 2-like adrenoceptors in canine arterial and venous smooth muscle.
Topics: 1-Naphthylamine; Animals; Clonidine; Dogs; Electric Stimulation; Femoral Artery; Femoral Vein; Imidazoles; Methoxamine; Muscle, Smooth, Vascular; Norepinephrine; Phenylephrine; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Saphenous Vein; Splenic Artery; Verapamil | 1981 |
Reversal of alpha 1-receptor mediated relaxation in intestinal smooth muscle.
Topics: Animals; Clonidine; Electrolytes; Female; Guinea Pigs; Intestines; Male; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Phenylephrine; Rabbits; Receptors, Adrenergic; Receptors, Adrenergic, beta; Verapamil | 1981 |
Interaction of verapamil with human platelet alpha-adrenergic receptors.
Topics: Binding, Competitive; Blood Platelets; Clonidine; Dihydroergotoxine; Epinephrine; Humans; Kinetics; Platelet Aggregation; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Verapamil; Yohimbine | 1982 |
The interaction of calcium antagonists (slow channel blockers) with myocardial alpha adrenoceptors.
Topics: Animals; Brain; Calcium Channel Blockers; Clonidine; Diltiazem; Gallopamil; In Vitro Techniques; Male; Myocardium; Nifedipine; Rats; Rats, Inbred Strains; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Verapamil | 1982 |
[The hypertensive crisis].
Topics: Acute Disease; Calcium Channel Blockers; Clonidine; Coronary Disease; Diazoxide; Dihydralazine; Diltiazem; Heart Failure; Humans; Hypertension; Nifedipine; Nitroprusside; Sympatholytics; Verapamil | 1984 |
Decrease in bradycardic effect of AQ-A 39 and alinidine in guinea-pig sinoatrial node depolarized by high external K+-concentration.
Topics: Animals; Clonidine; Depression, Chemical; Guinea Pigs; Heart Rate; In Vitro Techniques; Isoindoles; Neuromuscular Depolarizing Agents; Phthalimides; Potassium; Sinoatrial Node; Verapamil | 1984 |
Comparison of the bradycardic effects of alinidine (St 567), AQ-A 39 and verapamil on guinea-pig sinoatrial node superfused with different Ca2+ and NaCl solutions.
Topics: Animals; Calcium; Clonidine; Electrophysiology; Female; Guinea Pigs; Heart Rate; In Vitro Techniques; Isoindoles; Male; Phthalimides; Sinoatrial Node; Sodium Chloride; Verapamil | 1983 |
Inhibition by D 600 of norepinephrine- and clonidine-induced responses of the aortae from normotensive (WKY) and spontaneously hypertensive rats (SHR).
Topics: Animals; Aorta; Calcium Channel Blockers; Clonidine; Gallopamil; Hypertension; In Vitro Techniques; Norepinephrine; Rats; Rats, Inbred Strains; Vasoconstriction; Verapamil | 1982 |
Protective effects of clonidine and verapamil in experimental amitriptyline poisoning in rabbits.
Topics: Amitriptyline; Animals; Blood Pressure; Clonidine; Dose-Response Relationship, Drug; Electrocardiography; Female; Male; Rabbits; Verapamil | 1982 |
The effects of drugs on the exercise electrocardiogram.
Topics: Cardiovascular Agents; Clonidine; Double-Blind Method; Electrocardiography; Exercise Test; Heart Rate; Hemodynamics; Humans; Propranolol; Vasodilator Agents; Verapamil | 1981 |
Acute hypertensive crises.
Topics: Acute Disease; Adult; Aged; Clonidine; Diazoxide; Heart Block; Humans; Hypertension; Injections, Intravenous; Myocardial Infarction; Nitroprusside; Reserpine; Verapamil | 1980 |
Role of L-type calcium channels on yohimbine-precipitated clonidine withdrawal in vivo and in vitro.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Behavior, Animal; Calcium Channels; Clonidine; Diltiazem; Dose-Response Relationship, Drug; Drug Implants; Female; Ileum; In Vitro Techniques; Isomerism; Mice; Muscle Contraction; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Verapamil; Yohimbine | 1993 |
Calcium channel blockers impair the pituitary-adrenocortical responses to central adrenergic receptors stimulation.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Animals; Clonidine; Corticosterone; Drug Interactions; Hypothalamo-Hypophyseal System; Isoproterenol; Male; Nifedipine; Phenylephrine; Pituitary-Adrenal System; Rats; Rats, Wistar; Stimulation, Chemical; Verapamil | 1993 |
Effects of subchronic exposure of rats to lead or zinc on alpha-adrenoceptor-mediated contractile responses in isolated vas deferens.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Clonidine; Electric Stimulation; In Vitro Techniques; Lead; Male; Muscle Contraction; Muscle, Smooth; Nitrendipine; Norepinephrine; Phenylephrine; Rats; Rats, Wistar; Receptors, Adrenergic, alpha; Sulfates; Vas Deferens; Verapamil; Yohimbine; Zinc Compounds; Zinc Sulfate | 1993 |
Differential cerebrovascular responsiveness in spontaneously hypertensive rats following antihypertensive treatment with clonidine and verapamil.
Topics: Animals; Blood Pressure; Body Weight; Cerebrovascular Circulation; Clonidine; Heart Rate; Hypertension; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Time Factors; Verapamil | 1993 |
Effects of verapamil on electroconvulsive shock- and clonidine-induced amnesia.
Topics: Adrenergic alpha-Agonists; Amnesia; Animals; Avoidance Learning; Calcium Channel Blockers; Clonidine; Electroshock; Male; Rats; Rats, Wistar; Verapamil | 1997 |
Drug induced contraction and relaxation in mouse isolated aorta.
Topics: 1-Methyl-3-isobutylxanthine; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Aorta; Bethanechol; Clonidine; Electric Stimulation; In Vitro Techniques; Male; Mice; Mice, Inbred ICR; Muscarinic Agonists; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Neuromuscular Depolarizing Agents; Nitroprusside; Norepinephrine; Phosphodiesterase Inhibitors; Potassium Chloride; Prazosin; Serotonin; Vasoconstrictor Agents; Vasodilator Agents; Verapamil | 1997 |
Differential blockade of alpha,beta-methylene-ATP, noradrenaline and electrically evoked contractions of the rat vas deferens.
Topics: Adenosine Triphosphate; Adrenergic alpha-Antagonists; Animals; Clonidine; Cromakalim; Drug Interactions; Electric Stimulation; In Vitro Techniques; Male; Nifedipine; Norepinephrine; Papaverine; Rats; Rats, Wistar; Vas Deferens; Vasoconstrictor Agents; Vasodilator Agents; Verapamil | 1999 |
The mechanisms of alpha(2)-adrenoceptor agonist-induced contraction in longitudinal muscle of the porcine uterus.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Calcium; Calcium Channel Blockers; Clonidine; Colforsin; Cyclic AMP; Female; Fluorescent Dyes; Fura-2; In Vitro Techniques; Muscle Contraction; Muscle, Smooth; Myometrium; Pertussis Toxin; Quinoxalines; Swine; Uterus; Verapamil; Virulence Factors, Bordetella | 2000 |
The differential effects of calcium channel blockers in the behavioural despair test in mice.
Topics: Animals; Antidepressive Agents; Calcium Channel Blockers; Clomipramine; Clonidine; Cyproheptadine; Depression; Desipramine; Diltiazem; Drug Interactions; Female; Male; Mianserin; Mice; Motor Activity; Nifedipine; Tranylcypromine; Verapamil | 2000 |
Role of calcium channels in the spinal transmission of nociceptive information from the mesentery.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Adrenergic alpha-Agonists; Analgesics, Opioid; Animals; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Calcium Channels, N-Type; Clonidine; Dose-Response Relationship, Drug; Female; Mesentery; Morphine; omega-Conotoxins; Pain; Rats; Rats, Sprague-Dawley; Spinal Cord; Synaptic Transmission; Verapamil | 2001 |
Intracellular alkalinization augments alpha(1)-adrenoceptor-mediated vasoconstriction by promotion of Ca(2+) entry through the non-L-type Ca(2+) channels.
Topics: Adrenergic alpha-Agonists; Ammonium Chloride; Animals; Aorta; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Clonidine; Dose-Response Relationship, Drug; Drug Synergism; Guinea Pigs; Hydrogen-Ion Concentration; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Phenylephrine; Phorbol 12,13-Dibutyrate; Potassium Chloride; Propionates; Receptors, Adrenergic, alpha-1; Vasoconstriction; Verapamil | 2001 |
Blood pressure changes after intrathecal co-administration of calcium channel blockers with morphine or clonidine at the spinal level.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Animals; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Clonidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Injections, Spinal; Morphine; omega-Conotoxins; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Spinal Cord; Verapamil | 2002 |
An inherent acceleratory effect of insulin on small intestinal transit and its pharmacological characterization in normal mice.
Topics: Animals; Atropine; Calcium Channels; Clonidine; Gastrointestinal Transit; Glyburide; Insulin; Insulin Secretion; Intestine, Small; Male; Mice; Naloxone; Ondansetron; Receptors, Opioid; Verapamil | 2006 |
Functional and Pharmacological Comparison of Human, Mouse, and Rat Organic Cation Transporter 1 toward Drug and Pesticide Interaction.
Topics: Animals; Catecholamine Plasma Membrane Transport Proteins; Clonidine; Drug Interactions; Fungicides, Industrial; HEK293 Cells; Humans; Mice; Rats; Species Specificity; Verapamil | 2020 |